1The COVID-19 pandemic is spreading globally with high disparity in the 2 susceptibility of the disease severity. Identification of the key underlying factors for 3 this disparity is highly warranted. Here we describe constructing a proteomic risk 4 score based on 20 blood proteomic biomarkers which predict the progression to 5 severe COVID-19. We demonstrate that in our own cohort of 990 individuals without 6 infection, this proteomic risk score is positively associated with proinflammatory 7 cytokines mainly among older, but not younger, individuals. We further discovered 8 that a core set of gut microbiota could accurately predict the above proteomic 9 biomarkers among 301 individuals using a machine learning model, and that these gut 10 microbiota features are highly correlated with proinflammatory cytokines in another 11 set of 366 individuals. Fecal metabolomic analysis suggested potential amino 12 acid-related pathways linking gut microbiota to inflammation. This study suggests 13 that gut microbiota may underlie the predisposition of normal individuals to severe : medRxiv preprint ( Figure S1). Gut microbiota data were collected and measured during a follow-up 107 visit of the cohort participants, with a cross-sectional subset of the individuals (n=132) 108 having blood proteomic data at the same time point as the stool collection and another 109 independent prospective subset of the individuals (n=169) having proteomic data at a 110 next follow-up visit ~3 years later than the stool collection. 111 112 Among the cross-sectional subset, using a machine learning-based method: 113 LightGBM and a very conservative and strict tenfold cross-validation strategy, we 114 identified 20 top predictive operational taxonomic units (OTUs), and this subset of 115 core OTUs explained an average 21.5% of the PRS variation (mean out-of-sample 116 R 2 =0.215 across ten cross-validations). The list of these core OTUs along with their 117 taxonomic classification is provided inTable S3. These OTUs were mainly assigned 118 to Bacteroides genus, Streptococcus genus, Lactobacillus genus, Ruminococcaceae 119 family, Lachnospiraceae family and Clostridiales order.120 121To test the verification of the core OTUs, the Pearson correlation analysis showed the 122 coefficient between the core OTUs-predicted PRS and actual PRS reached 0.59 123 (p<0.001), substantially outperforming the predictive capacity of other demographic 124 characteristics and laboratory tests including age, BMI, sex, blood pressure and blood 125 lipids (Pearson's r =0.154, p=0.087) ( Figure 3A). Additionally, we used co-inertia 126 analysis (CIA) to further test co-variance between the 20 identified core OTUs and 20 127 predictive proteomic biomarkers of severe COVID-19, outputting a RV coefficient 128 (ranged from 0 to 1) to quantify the closeness. The results indicated a close 129 association of these OTUs with the proteomic biomarkers (RV=0.12, p<0.05) (Figure 130 S3A). When replicating this analysis stratified by age, significant association was 131 observed...
Obesity and associated metabolic disorders are worldwide public health issues. The gut microbiota plays a key role in the pathophysiology of diet-induced obesity. Glycerol monolaurate (GML) is a widely consumed food emulsifier with antibacterial properties. Here, we explore the anti-obesity effect of GML (1,600 mg/kg of body weight) in high-fat diet (HFD)-fed mice. HFD-fed mice were treated with 1,600 mg/kg GML. Integrated microbiome, metabolome, and transcriptome analyses were used to systematically investigate the metabolic effects of GML, and antibiotic treatment was used to assess the effects of GML on the gut microbiota. Our data indicated that GML significantly reduced body weight and visceral fat deposition, improved hyperlipidemia and hepatic lipid metabolism, and ameliorated glucose homeostasis and inflammation in HFD-fed mice. Importantly, GML modulated HFD-induced gut microbiota dysbiosis and selectively increased the abundance of Bifidobacterium pseudolongum. Antibiotic treatment abolished all the GML-mediated metabolic improvements. A multiomics (microbiome, metabolome, and transcriptome) association study showed that GML significantly modulated glycerophospholipid metabolism, and the abundance of Bifidobacterium pseudolongum strongly correlated with the metabolites and genes that participated in glycerophospholipid metabolism. Our results indicated that GML may be provided for obesity prevention by targeting the gut microbiota and regulating glycerophospholipid metabolism.
Our results indicate that relatively low-dose GML consumption promotes metabolic syndrome, gut microbiota dysbiosis, and systemic low-grade inflammation, thereby calling for a reassessment of GML usage.
OBJECTIVE To identify the core gut microbial features associated with type 2 diabetes risk and potential demographic, adiposity, and dietary factors associated with these features. RESEARCH DESIGN AND METHODS We used an interpretable machine learning framework to identify the type 2 diabetes–related gut microbiome features in the cross-sectional analyses of three Chinese cohorts: one discovery cohort (n = 1,832, 270 cases of type 2 diabetes) and two validation cohorts (cohort 1: n = 203, 48 cases; cohort 2: n = 7,009, 608 cases). We constructed a microbiome risk score (MRS) with the identified features. We examined the prospective association of the MRS with glucose increment in 249 participants without type 2 diabetes and assessed the correlation between the MRS and host blood metabolites (n = 1,016). We transferred human fecal samples with different MRS levels to germ-free mice to confirm the MRS–type 2 diabetes relationship. We then examined the prospective association of demographic, adiposity, and dietary factors with the MRS (n = 1,832). RESULTS The MRS (including 14 microbial features) consistently associated with type 2 diabetes, with risk ratio for per 1-unit change in MRS 1.28 (95% CI 1.23–1.33), 1.23 (1.13–1.34), and 1.12 (1.06–1.18) across three cohorts. The MRS was positively associated with future glucose increment (P < 0.05) and was correlated with a variety of gut microbiota–derived blood metabolites. Animal study further confirmed the MRS–type 2 diabetes relationship. Body fat distribution was found to be a key factor modulating the gut microbiome–type 2 diabetes relationship. CONCLUSIONS Our results reveal a core set of gut microbiome features associated with type 2 diabetes risk and future glucose increment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.